

Onconova Therapeutics, Inc.  
Form 4  
August 01, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Michael & Jane Hoffman 2013  
Descendants

2. Issuer Name and Ticker or Trading Symbol  
Onconova Therapeutics, Inc.  
[ONTX]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
  
712 FIFTH AVENUE, 36TH FLOOR  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
07/30/2013

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
 10% Owner  
\_\_\_\_ Other (specify below)

NEW YORK, NY 10019

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2013		C		83,857	A	(1) 728,517
Common Stock	07/30/2013		C		105,363	A	(2) 833,880
Common Stock	07/30/2013		C		266,712	A	(3) 1,100,592
Common Stock	07/30/2013		C		476,087	A	(4) 1,576,679
Common Stock	07/30/2013		C		85,744	A	(5) 1,662,423

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Common Stock	07/30/2013	C	172,411	A	(6)	1,834,834	D
Common Stock	07/30/2013	C	226,024	A	(7)	2,060,858	D
Common Stock	07/30/2013	C	1,226,942	A	(8)	3,287,800	D
Common Stock	07/30/2013	P	1,000,000	A	\$ 15	4,287,800	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number of Shares
Series B Convertible Preferred Stock	(1)	07/30/2013		C		99,350	(1)	(1)	Common Stock	83,8
Series C Convertible Preferred Stock	(2)	07/30/2013		C		140,449	(2)	(2)	Common Stock	105,3
Series D Convertible Preferred Stock	(3)	07/30/2013		C		355,528	(3)	(3)	Common Stock	266,7
Series E Convertible Preferred Stock	(4)	07/30/2013		C		634,625	(4)	(4)	Common Stock	476,0
Series F Convertible Preferred Stock	(5)	07/30/2013		C		111,227	(5)	(5)	Common Stock	85,7

Series G Convertible Preferred Stock	<u>(6)</u>	07/30/2013	C	229,825	<u>(6)</u>	<u>(6)</u>	Common Stock	172,4
Series H COnvertible Preferred Stock	<u>(7)</u>	07/30/2013	C	301,290	<u>(7)</u>	<u>(7)</u>	Common Stock	226,0
Series I Convertible Preferred Stock	<u>(8)</u>	07/30/2013	C	1,635,514	<u>(8)</u>	<u>(8)</u>	Common Stock	1,226

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Michael & Jane Hoffman 2013 Descendants 712 FIFTH AVENUE, 36TH FLOOR NEW YORK, NY 10019			X	

## Signatures

/s/ Ajay Bansal, as attorney  
in fact

07/30/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Series B Convertible Preferred Stock converted into Common Stock on a 0.85-for-1 basis and had no expiration date.
- (2) The Series C Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (3) The Series D Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (4) The Series E Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (5) The Series F Convertible Preferred Stock converted into Common Stock on a 0.77-for-1 basis and had no expiration date.
- (6) The Series G Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (7) The Series H Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (8) The Series I Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.